foxo4 dri senolytic peptide human trial 2024

foxo4 dri senolytic peptide human trial 2024 FOXO4-DRI Dosing Guide: Peptide Protocol (June 2026) Peptide inhibitors targeting FOXO4-p53 interactions

Name: foxo4 dri senolytic peptide human trial 2024 FOXO4-DRI Dosing Guide: Peptide Protocol (June 2026) Peptide inhibitors targeting FOXO4-p53 interactions
Brand: equiscorp.hu
SKU: 66628831742
Price: 29.16 USD
Availability: InStock
Rating: 4.2916 (8 reviews)

Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment npj Aging The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications

SKU: 66628831742 · From equiscorp.hu

4.3

USD29.16 USD72.16

Pay in 4 interest-free payments of $7.29 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Description

Hufig gestellte Fragen (FAQ) 1

Health benefits Vitamin B12 is crucial to various bodily processes, including normal functioning of the brain and nervous system, cognitive functioning (ability to think), formation of red blood cells and prevention of anaemia